Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68. - Wikidata - wikimedia - TriplyDB

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.

http://www.wikidata.org/entity/Q33988096

about

Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter Oncolytic virotherapy of canine and feline cancer Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68 Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models.Inducible gene expression in tumors colonized by modified oncolytic vaccinia virus strains Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice.Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.Development of new therapy for canine mammary cancer with recombinant measles virus.On the potential of oncolytic virotherapy for the treatment of canine cancers.Evaluation of the oncolytic potential of R2B Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620).Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma.Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice.Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68.Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine.Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway.Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma

P2860

Q21134124-ECF9CCD4-12C7-4788-849F-C045284F0B1B Q27008306-8248C228-09FB-4D9D-A445-63A2D825AA4A Q28729948-8FE0A1E9-4D90-43BC-842C-31EDE6B61A61 Q28742749-83C5ED94-8C29-40A2-855C-EDD7222D0B67 Q33927165-27EBDC51-B24A-49EF-AAEA-6FF3A2E8E1F7 Q34005213-A1973C69-086C-4FD8-8AFB-4A56E482F060 Q34142957-674821D8-FED3-4B8E-9486-9630D4A97728 Q34262005-21F4E6F2-7623-4743-8DB1-925836006A7E Q34307934-F7EE5560-6DB1-4AEC-BAA4-9119188E5A14 Q34455259-A903DE0E-EF63-458C-875B-EBCF75FC7A51 Q35338417-AE203C58-502A-4987-B96E-B6E678104727 Q35895339-B92C5B39-FF18-452C-AB06-9053127CCBA1 Q35963805-F0930852-A77B-4BA4-91D4-5055BC28016C Q36099082-74DA93CD-D861-4CF5-817A-6089A4E7A2B0 Q36664263-72D80ED8-4640-4661-A579-2F1B12B98D33 Q37031925-F453880D-4A54-4887-86A4-49ACBFB6B6BA Q38701351-F81C53D5-4F80-4451-B067-0AFB1BCE9D29 Q38818452-807392BF-76F3-4923-842B-E86BD105621B Q39139854-983AA307-BE51-4EE1-9A88-41B75BB44B70 Q39175316-2C86358D-3038-4EF8-9CD3-B6B0A5A8DAE9 Q40162348-FA0B214E-6678-47ED-9212-6BBA62421C03 Q41706553-AAB254DB-6A1B-47B0-95CB-692C626B23A7 Q52591426-DDA25701-530D-416F-9311-E97A5EC1E9A3 Q59117175-EAF4BE20-DE3D-4DAF-81EE-E8B52D06620F

P2860

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.

http://www.wikidata.org/entity/Q33988096

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Significant Growth Inhibition ...... lytic Vaccinia Virus GLV-1h68.

@ast

Significant Growth Inhibition ...... lytic Vaccinia Virus GLV-1h68.

@en

type

label

Significant Growth Inhibition ...... lytic Vaccinia Virus GLV-1h68.

@ast

Significant Growth Inhibition ...... lytic Vaccinia Virus GLV-1h68.

@en

prefLabel

Significant Growth Inhibition ...... lytic Vaccinia Virus GLV-1h68.

@ast

Significant Growth Inhibition ...... lytic Vaccinia Virus GLV-1h68.

@en

P1433

Q33988096-FDD7E7BA-9931-4BFF-9EE1-64846680728F

P1476

Q33988096-9CBA5BB8-F7F7-4C6E-B6C3-A588C9E97048

P2093

Q33988096-110FE3F6-EA65-4761-B5CF-5CFEE9B05946

Q33988096-38035374-E7CA-4E5C-83F1-701774B8E0A1

Q33988096-45A48FF0-A183-43FE-9B8A-3036AAEBD873

Q33988096-5365200E-F62A-46D5-AD0C-C5908A1AF58E

Q33988096-58931172-E288-4130-A75E-FDEBEE3A99FA

Q33988096-5C299828-B430-40BE-BA61-9D19A295F473

Q33988096-667055E2-46CC-444F-A4BB-3C656985CAF9

Q33988096-E85C6458-33CF-4D3F-B087-8BFFC63E369B

Q33988096-EEE5265E-2BDC-4A33-B716-FFF24A141C05

Q33988096-F5C69639-755F-42F6-81EA-BA7F07427D01

P2860

Q33988096-05385F61-015F-4698-A115-1B6F493A6F8A

Q33988096-12E2241D-6C8F-41D2-897B-D03D3D1725D6

Q33988096-520FD60F-927E-4742-B210-A2B525BC827D

Q33988096-560DF5C1-2460-4B09-9E8A-CF3DDABD75EB

Q33988096-6CA318FB-A6EC-4D3C-8ED5-B79B1E661F01

Q33988096-74E6E262-EDE1-433D-8FA0-53339E3FC4F3

Q33988096-7DE46A12-764D-4043-81B0-107FFD5DBF8F

Q33988096-851B1A77-A838-4C89-BABF-085F86CAAF7F

Q33988096-961AA17E-7DCE-4189-BF86-4F294FB24F48

Q33988096-A51CF3B1-D5FE-47DE-847D-2BB196284394

P304

Q33988096-46C092A5-4B06-4913-84D3-D54226786B99

P31

Q33988096-E86C6898-BCB6-44DB-BBCF-4E5E1AF3D634

P356

Q33988096-755D2A64-309E-449D-9CBB-07B4A6C61478

P478

Q33988096-9E92FF2E-E6AE-424B-834D-09A80CCF44A7

P50

Q33988096-7F65CB20-FDDA-48E8-82EC-4BD02EB2C228

P577

Q33988096-E11E5669-41C7-417B-8D9E-B3A39007F74E

P5875

Q33988096-3522D990-6993-414B-9E15-BD85C5AB07D1

P698

Q33988096-AF2AB693-AB9E-4D6F-83C5-D4A8350F4915

P921

Q33988096-9B773D29-8286-4975-A747-B1D17E5E0816

Q33988096-C17A1109-5386-44A5-8CEF-3713630FE305

P932

Q33988096-C3CF567C-55CD-4401-B8B1-A2E16C976802

P356

P1433

Journal of oncology

P1476

Significant Growth Inhibition ...... lytic Vaccinia Virus GLV-1h68.

@en

P2093

Ingo Nolte

http://www.w3.org/2001/XMLSchema#string

Ivaylo Gentschev

http://www.w3.org/2001/XMLSchema#string

Jochen Stritzker

http://www.w3.org/2001/XMLSchema#string

Jörn Bullerdiek

http://www.w3.org/2001/XMLSchema#string

Klaas Ehrig

http://www.w3.org/2001/XMLSchema#string

Michael Hess

http://www.w3.org/2001/XMLSchema#string

Nanhai Chen

http://www.w3.org/2001/XMLSchema#string

Qian Zhang

http://www.w3.org/2001/XMLSchema#string

Stephan Rudolph

http://www.w3.org/2001/XMLSchema#string

Ulrike Donat

http://www.w3.org/2001/XMLSchema#string

P2860

Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.

Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.

From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development.

Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Canine mammary gland tumors.

The immunologic aspects of poxvirus oncolytic therapy

Complex mammary tumours in the female dog: a review.

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.

P304

736907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2010/736907

http://www.w3.org/2001/XMLSchema#string

P478

2010

http://www.w3.org/2001/XMLSchema#string

P50

Aladar A Szalay

P577

2010-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45189139

http://www.w3.org/2001/XMLSchema#string

P698

20631910

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

2902752

http://www.w3.org/2001/XMLSchema#string